MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines—an advance that could lead to much ...
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active ...
We have now activated 6 qualified treatment centers or QTCs, treated our fifth commercial patient with manufacturing underway for the sixth and scheduled additional patients throughout the current ...
Fifteen years ago, doctors in Europe noticed a remarkable thing happening in people with chronic hepatitis B infections. When patients went off their medications, the virus started to come back—and ...
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund ...
FDA feedback on the Auxora pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling ...
Scientists’ discovery of a molecular “switch” that activates an energy‑burning pathway in mice has the potential to lead to new treatments for bone disease. The study, published in Nature, sheds new ...
According to Johnson, it took over a year to scrub the microplastics from his sperm. There are three main interventions he ...
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential ...
Sciencing on MSN
What scientists know about death that you didn't (until now)
Death is the great equalizer, but it's also one of science's greatest mysteries, with researchers having made some strange ...
Tad Dryden, MD, discussed how TL1A inhibition may produce dual anti-inflammatory and antifibrotic outcomes in Crohn disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results